Jennifer Hill, MD
Allergy & Immunology · Scottsdale, AZNPI 1497035604
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $258,011 of the $334,607 with a category attached, or 77.1%. 39 manufacturers reported payments, led by AstraZeneca at 40.0% of the total. Among allergy & immunology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 812 payments — averaging $412.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$134K
- Sanofi$62K
- Regeneron Healthcare Solutions, Inc.$54K
- Optinose US, Inc.$49K
- GSK$9K
- Novartis$8K
- plus $19K from 33 others
Across 39 payments — averaging $2144.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Optinose US, Inc.$53K
- Novartis$17K
- Regeneron$14K
What the payments were for
- Consulting fees$47,30414%
- Speaking & faculty fees$258,01177%
- Travel & lodging$11,8574%
- Food & beverage$16,8985%
- Education$5370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 230 | $133,958 |
| Sanofi | 104 | $61,582 |
| Regeneron Healthcare Solutions, Inc. | 104 | $54,249 |
| Optinose US, Inc. | 109 | $48,599 |
| GSK | 33 | $9,169 |
| Novartis | 29 | $7,685 |
| Amgen | 26 | $7,455 |
| Genentech USA, Inc. | 13 | $4,566 |
| Regeneron | 2 | $3,198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 48 | $694 |
| Allerderm Laboratories | 1 | $500 |
| Pfizer | 21 | $404 |
| Blueprint Medicines Corporation | 3 | $317 |
| CSL Behring | 10 | $258 |
| Pharming Healthcare, Inc. | 10 | $219 |
| Circassia Inc. | 2 | $189 |
| Cycle Pharmaceuticals Inc | 4 | $181 |
| Biocryst US Sales Co., LLC | 8 | $163 |
| Incyte Corporation | 6 | $158 |
| ADMA Biomanufacturing LLC | 12 | $143 |
| Organon | 4 | $142 |
| Grifols USA, LLC | 5 | $109 |
| Kaleo, Inc. | 4 | $102 |
| Octapharma USA, Inc. | 4 | $94 |
| Sanofi-aventis U.S. LLC | 2 | $82 |
| Lilly USA, LLC | 2 | $76 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $52 |
| Ionis Pharmaceuticals, Inc. | 2 | $51 |
| Shire North American Group Inc | 2 | $33 |
| Galderma Laboratories, L.p. | 1 | $28 |
| Alk-abello, Inc | 1 | $25 |
| AbbVie | 1 | $18 |
| Tersera Therapeutics LLC | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| GC Biopharma USA, Inc. | 1 | $14 |
| Greer Laboratories, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$334,607 in reported general payments places this provider in the 95th percentile of 90 allergy & immunology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 39 | $145,610 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 31 | $56,258 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,317 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,964 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,613 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,163 |
| Epinephrine | 24 | $3,109 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $2,860 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,803 |
| Azelastine Hcl | 31 | $1,387 |
| Pantoprazole Sodium | 22 | $432 |
| Ipratropium Bromide | 13 | $428 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $346 |
| Montelukast Sodium | 14 | $282 |
| Fluticasone Propionate | 13 | $194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $258 | $145,61039 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $694 | $56,25831 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $9,169 | $23,28137 claims |
| Boehringer IngelheimSpiriva Respimat | $15 | $5,61311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 allergy & immunology providers in Arizona.
Other allergy & immunology in Scottsdale
- Michael ManningScottsdale$1.1M
- Jean NelsonScottsdale$183K
- Kiranjit KhalsaScottsdale$124K
- Sanjay PatelScottsdale$21K
- Hiral ThakrarScottsdale$19K
- Rachael StillwagonScottsdale$7K
- Rebecca KoenigsbergScottsdale$3K
- Aaron DavisScottsdale$3K
- Matthew RankScottsdale$1K
- Neal JainGilbert$388K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.